Project Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Treatment of autism spectrum disorders with a glutamate antagonist  

Riluzole, a glutamate antagonist, reduces symptoms in adults with obsessive-compulsive disorder (OCD). Preliminary data will be collected on Riluzole efficacy and safety in children and adolescents with co-morbid conditions of ASD and OCD. Project Status
ONGOING

2009

Funder National Institutes of Health
Fiscal Year Funding $203,517.00
Project Number 1ZIAMH002913-02
Principal Investigator Swedo, Susan
Received ARRA Funding? No
Strategic Plan Question Question 4: Which Treatments And Interventions Will Help? (Interventions)
Strategic Plan Objective Yellow dot: Objective has some degree of funding, but less than the recommended amount. 4SC. Test safety and efficacy of at least five widely used interventions (e.g., nutrition, medications, assisted technologies, sensory integration, medical procedures) that have not been rigorously studied for use in ASD by 2012. IACC Recommended Budget: $27,800,000 over 5 years.
Federal or Private? Federal
Institution National Institutes of Health (NIH)
State/Country Maryland
Web Link 1 Treatment of autism spectrum disorders with a glutamate antagonist (External web link)
Web Link 2 No URL available.
Web Link 3 No URL available.
New! History/Related Projects Treatment of autism spectrum disorders with a glutamate antagonist | $465,840.00 | 2008 | Z01MH002913-01